Lifeward Ltd.

Lifeward Ltd. develops and commercializes mobility and rehabilitation technologies for people with spinal cord injury and other mobility-limiting conditions. Its portfolio centers on the ReWalk personal exoskeleton, AlterG anti-gravity systems, ReStore, and MyoCycle, with revenue also coming from warranties and repair services.

−87,8 %

38,3 %

−90,4 %

−14,1 %

1.31

0.84

— Lifeward Ltd.
%
Exoskeleton mobility systems45% Wearable robotic devices used by individuals with spinal cord injury to stand and walk.
Rehabilitation and anti-gravity systems35% Clinic-based systems such as AlterG and ReStore used for therapy, gait training, and recovery.
Home and personal therapy devices10% Smaller devices such as MyoCycle sold to rehabilitation users and personal users.
Services and support10% Extended warranties, repairs, and related post-sale support for installed products.

Lifeward sells to a mix of end users and institutional buyers, with direct sales in the United States and...

  • Rehabilitation clinics and centersprimary

    Buy AlterG, ReStore, and related systems for therapy, gait training, and patient rehabilitation.

  • SCI patients and self-pay individualsprimary

    Purchase ReWalk personal exoskeletons and MyoCycle devices for mobility and home use.

  • Third-party payors and government programsprimary

    Do not buy directly, but determine reimbursement access that drives adoption of ReWalk systems.

  • Distributors and channel partnerssecondary

    Buy or resell products in non-direct markets and provide local market access and service coverage.

  • Sports teamssecondary

    Use AlterG systems for training, recovery, and performance applications.

Lifeward’s principal markets are the United States and Europe, with smaller sales in Asia, the Middle East, and South...

  • •United States is the main direct-sales market and reimbursement focus
  • •Europe is a major market, with direct and distributor sales in Germany
  • •Canada is served through a mix of direct sales and distributors
  • •Smaller sales come from Asia, the Middle East, and South America
  • •Operations span Israel, the U.S., and Germany, affecting supply and support

Lifeward is focused on expanding reimbursement coverage for ReWalk, especially through commercial and government...

01
Reimbursement expansion for ReWalkshort-term

Coverage determines adoption for a high-cost device and directly affects sales conversion.

02
Commercialization of ReWalk 7 in Europeshort-term

CE mark approval enables broader European sales and diversifies the revenue base.

03
Cost reduction and operational efficiencymedium-term

Lower material costs and leaner operations are important given losses and limited liquidity.

04
Broaden product portfolio penetrationmedium-term

Growth depends on selling more AlterG and MyoCycle units across rehab and personal channels.

Lifeward faces execution risk from its manufacturing transition, reimbursement dependence, and limited liquidity...

critical

Going-concern and financing risk

Cash resources are limited and the company expects further losses, requiring additional financing.

Scope
Operations continuity and dilution risk
Materiality
high
high

Manufacturing transition to in-house production

The company moved ReWalk manufacturing away from Sanmina and must build internal capabilities and supplier relationships.

Scope
ReWalk product supply, quality control, and cost structure
Materiality
high
high

Reimbursement and coverage uncertainty

Demand for exoskeletons depends heavily on third-party payor support, which is not uniform in the U.S.

Scope
ReWalk sales conversion and market adoption
Materiality
high
medium

Tariffs and trade barriers

The company relies on foreign manufacturers and parts suppliers, including in China, Taiwan, and Israel.

Scope
Input costs, pricing, and gross margin
Materiality
high
medium

Nasdaq Capital Market compliance

Failure to satisfy listing requirements could threaten continued listing and liquidity in the stock.

Scope
Capital markets access and share price volatility
Materiality
high
Revenue recognition for devices, warranties, and repairs
Can shift reported revenue and gross margin between periods
Intangible asset amortization
Impacts sales and marketing or operating expense trends
Going-concern assessment
Affects disclosure, financing assumptions, and investor risk assessment
Deferred tax and subsidiary timing differences
Can create volatility in reported tax expense

LiveWire Group, Inc.

LVWR · Motorcycles, Bicycles & Parts

INTEGRA LIFESCIENCES HOLDINGS CORP

IART · Surgical & Medical Instruments & Apparatus

Woodward, Inc.

WWD · Electrical Industrial Apparatus

Redwire Corp

RDW · Guided Missiles & Space Vehicles & Parts

Dogwood Therapeutics, Inc.

DWTX · Pharmaceutical Preparations

IR-Med, Inc.

Electromedical & Electrotherapeutic Apparatus

: 28/04/2026